Telo Genomics Announces $250,000 Term Loan Facility

Telo Genomics secures $250,000 loan, receives $100,000 initial advance at 15.60% annual interest.

What the company is saying

Telo Genomics Corp. (TSXV:TELO, OTCQB:TDSGF) is announcing the closing of a secured term loan agreement with BrightArc Capital Adminco 1 Inc. for a principal amount of $250,000, effective October 29, 2026. The company emphasizes that it has received an initial advance of $100,000, with the balance to be advanced later, and that the loan is structured as a demand non-revolving facility. The release details the interest rate at 1.30% per month (15.60% annualized), monthly payments in arrears, and a minimum three-month interest payment if repaid early. Security for the loan includes a general security agreement over all present and after-acquired personal property, with specific reference to SR&ED claims, plus an irrevocable assignment of SR&ED tax credits and refunds. The company states that proceeds will fund general operating expenses and highlights covenants tied to timely SR&ED claim filings and direct deposit instructions for CRA payments. The tone is factual and focused on the mechanics and obligations of the facility, with no promotional language or unsupported claims.

What the data suggests

The company has closed a $250,000 term loan, of which $100,000 has been advanced as of the announcement date. The facility carries a high interest rate of 1.30% per month, equivalent to 15.60% per year, and requires monthly payments in arrears. Repayment is triggered by either the receipt of SR&ED claims for the 2026 tax year or twelve months from the advance date, whichever comes first. The loan is secured by all of the company's personal property and an irrevocable assignment of SR&ED tax credits and refunds, indicating the lender's focus on these credits as collateral. A three-month interest reserve is mandated and may be deducted from the advance, and early repayment within three months still requires a minimum of three months' interest. The agreement imposes strict covenants on the timing of SR&ED claim filings (within 180 days of the June 30 year end) and directs CRA payments to the lender. No operational or financial performance metrics beyond the loan terms are disclosed. The only clinical or product data referenced are legacy figures: over 190 peer-reviewed publications, 30+ clinical studies, and more than 3,000 patients, but these are not tied to the financing or current operations.

Analysis

The announcement is a factual disclosure of a secured term loan facility, detailing the principal amount, interest rate, security, covenants, and repayment triggers. The language is precise and avoids promotional or exaggerated claims, focusing on the mechanics of the loan and its intended use for general operating expenses. The only forward-looking elements are the use of proceeds and the timing of SR&ED claim receipts, both of which are standard in such financing updates and not presented in an inflated manner. There is no attempt to overstate the impact of the loan or to project outsized future benefits. No large capital outlay is paired with long-dated, uncertain returns; the facility is modest in size and structured for near-term operational funding. The gap between narrative and evidence is minimal, with all key claims supported by disclosed terms.

Risk flags

• ●The loan is secured by all present and after-acquired personal property and an irrevocable assignment of SR&ED tax credits and refunds, exposing the company to significant asset risk if it cannot meet repayment terms. If SR&ED claims are delayed, reduced, or denied, the company may have limited means to repay the loan, potentially resulting in loss of critical assets.
• ●The interest rate is high at 15.60% per year, which will add substantial cost to the company's operating expenses. If the company is unable to generate sufficient cash flow or receive SR&ED refunds promptly, the interest burden could exacerbate liquidity challenges.
• ●Strict covenants require timely SR&ED claim filings and direct deposit of CRA payments to the lender's account. Any failure to meet these administrative requirements could trigger default, accelerating repayment or enforcement of security, which could be disruptive to operations.

Bottom line

Telo Genomics has secured a $250,000 term loan, with $100,000 already advanced, to fund general operating expenses. The facility is expensive, carrying a 15.60% annual interest rate and secured by all company assets and SR&ED tax credits, making compliance and timely SR&ED claim processing critical. The loan structure and covenants place considerable operational and financial pressure on the company, especially if SR&ED refunds are delayed or denied. Investors should focus on the company's ability to file and collect SR&ED claims on schedule, as failure to do so could trigger repayment or asset forfeiture. The announcement provides full transparency on loan terms but does not address broader financial health or operational progress, so the most important takeaway is the company's reliance on SR&ED credits for near-term liquidity.

Announcement summary

(TSXV:TELO) (OTCQB:TDSGF) Telo Genomics Corp. announced it has closed a term loan agreement effective October 29, 2026, with BrightArc Capital Adminco 1 Inc. for a principal amount of $250,000. The term loan is a demand non-revolving facility. The company has received an initial advance of $100,000, with the remaining balance to be advanced at a later date. Interest on the loan accrues at a simple rate of 1.30% per month, which is equivalent to an annual rate of 15.60%, and is payable monthly in arrears. If the term loan is repaid within three months of advance, a minimum of three months of interest is payable. The facility is secured by a general security agreement over the company's present and after-acquired personal property, with specific reference to Scientific Research and Experimental Development (SR&ED) claims, and an irrevocable assignment of the company's SR&ED tax credits and refunds. Proceeds from the loan are to be used to fund the company's general operating expenses. The outstanding balance, including principal, accrued interest, and other amounts, is due on the earlier of three business days after the company receives its SR&ED claims for the tax year ended in 2026 or twelve months from the date of advance. An interest reserve equal to three months of interest is required and may be deducted from the advance. The term loan agreement includes covenants requiring timely filing of SR&ED claims within 180 days of the company's June 30 financial year end and maintenance of direct deposit instructions so that CRA payments are directed to the lender's account, as well as various negative covenants typical of this type of facility. Telo Genomics' lead application, Telo-MM, is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma. The company's proprietary technology has been substantiated in over 190 peer-reviewed publications and in more than 30 clinical studies involving over 3,000 patients with multiple cancers and Alzheimer's disease.

Disagree with this article?